Drug Information

General Information
Drug ID
DR00558
Drug Name
Erlotinib
Synonyms
4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; AQ4; CP 358,774; CP-358,774; CP-358774; Erlotinib Base; Erlotinib(Tarceva); Erlotinib, OS-774; Erlotinin; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; OSI 744; R 1415; Tarceva; Tarceva (TN); [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Drug Type
Small molecular drug
Indication Non-small cell lung cancer [ICD11: 2C25] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C22H23N3O4
Canonical SMILES
COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
InChI
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
InChIKey
AAKJLRGGTJKAMG-UHFFFAOYSA-N
CAS Number
CAS 183321-74-6
Pharmaceutical Properties Molecular Weight 393.4 Topological Polar Surface Area 74.7
Heavy Atom Count 29 Rotatable Bond Count 11
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
XLogP
3.3
PubChem CID
176870
PubChem SID
10258448 , 103177459 , 103905339 , 104425943 , 104831334 , 117695448 , 117866919 , 118049695 , 124893165 , 124893166 , 125001915 , 125343507 , 126622002 , 126653679 , 126670959 , 126670960 , 127301426 , 127301427 , 127301428 , 127301429 , 127301430 , 127301431 , 127301432 , 127301433 , 127301434 , 14720343 , 14878691 , 21317842 , 26757996 , 33500421 , 46508021 , 47957324 , 50068213 , 50100099 , 50405936 , 53788276 , 57395323 , 6593089 , 68530774 , 7885946 , 8035065 , 826174 , 85171065 , 85261833 , 85267493 , 87350514 , 92308781 , 92717787 , 93581027 , 94568883
ChEBI ID
CHEBI:114785
TTD Drug ID
D07POC
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [3]
References
1 Erlotinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
3 Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.